zilongwang/ReadingBank huggingface dataset:
On your Announcement page, copy and paste the following message to inform your students about BioSig, and let them know that the BioSig link can be found in the Start Here menu. Announcement message: Central Texas College has contracted with Biometric Signature ID to deploy BioSig-ID to positively verify student identity at various times throughout a course. This satisfies an accrediting agency requirement of verifying that the student who registered for the course is the person who is submitting coursework. If you have not done so in another course, you will need to establish your BioSig identity. This identity will be used for all CTC courses in which you enroll. 1. Watch this short to learn how to enroll with BioSig-ID. 2. The password you create will eventually be used for all courses at CTC, please try to remember it. However, if you forget, you can reset the password yourself. Watch this to learn how to reset your password. 3. Go to the Start Here on the course menu, click the "BioSig Registration" link to register and create a BioSig-ID password. The process should take you approximately four minutes. For BioSig technical assistance, please contact .
LBEC0101 (LG Chem Ltd) Enbrel 25mg Randomised, double-blind, single dose, two-treatment, crossover study Healthy volunteers (Korean n=43 completed PK analysis) 90% CI for the ratio of treatment means for area under the curve from time zero to the last quantifiable concentration (AUClast), from time zero extrapolated to infinite time (AUCinf) and maximal plasma concentration (Cmax) were within the limits of 80-125% for the comparison between LBEC0101 and Enbrel All subjects were anti-drug antibody (ADA) negative before the first dose. Five subjects showed a positive ADA result after conduct of Period 1, of which 1 received LBEC0101 and 4 received Enbrel. An additional 2 subjects showed a positive ADA results after conduct of Period 2, both of which received Enbrel. The incidence of ADA development was not significantly different between the treatments. [6] Trastuzumab ABP 980 (Amgen Inc) US and EU Herceptin (trastuzumab) Randomised, single-blind, single dose, three-arm, parallel group study (1:1:1) Healthy volunteers (n=148) 90% CI for the of treatment means for area under the curve from time zero to the last quantifiable concentration (AUClast), from time zero extrapolated to infinite time (AUCinf) and maximal plasma concentration (Cmax) were within the limits of 80-125% for the comparisons of ABP 980 with US Herceptin and ABP 980 with EU Herceptin, as well as for US and EU Herceptin. were no binding ADAs detected at baseline and no subjects developed binding or neutralising ADAs at the end of the study. [7] Bevacizumab existing pre- pre- trial
Biosimilar Candidate Reference Product Study Design Population PK Outcomes (and PD reported) Immunogenicity Outcomes Reference Etanercept PF-06438179 / GP1111 Remicade (EU and US) Randomised three arm PK study Healthy subjects (n=151, randomised 1:1:1) 90%CI for the between the geometric means of the from time zero extrapolated to infinite time (AUCinf), AUC from time 0 to the last measurable concentration (AUCT) and maximal plasma concentration (Cmax) were within the predefined bioequivalence interval of Anti-drug antibodies were detected in PF-06438179 / GP1111: 6 of 37 (16.2%) Remicade (EU): 14 of 43 (32.6%) Remicade (US): 11 of 39 (28.2%) [2] Peg-filgrastim trial
Neulasta (EU and US) Randomized, three-way crossover Healthy volunteers 216 subjects received at least one dose 208 subjects received at least two of the three doses PK: 90%CI for the ratio between the geometric means of the from time zero extrapolated to infinite time (AUCinf), and maximal plasma concentration (Cmax) were within the predefined bioequivalence interval of PD: 95% CI for the ratios of geometric means for the area under the curve above baseline for absolute neutrophil counts (ANC AUC0−t) and maximum change from baseline for ANC (ANC Cmax) were within the predefined PD equivalence interval of 0.8500 to 1.1765 After the first treatment period the proportion of subjects with anti-drug antibodies (excluding ADA positive at baseline) was: MYL-1401H: 14 of 63 (22%) Neulasta (EU): 16 of 68 (24%) Neulasta (US): 21 of 69 (30%) [3] Trastuzumab HD201 Herceptin (EU) Randomized, blinded, comparative PK study Healthy male subjects (n=73, randomised 1:1) 90%CI for the ratio between the geometric means of the from time zero extrapolated to infinite time (AUCinf), was within the predefined bioequivalence interval of No subjects were positive for antibodies on day 22 or 85 [4] An additional extension study to a phase I trial of rituximab was also reported and is described below. drug
Biosimilar Candidate Reference Product Study Design Study Population PK Outcomes (and PD where reported) Immunogenicity Outcomes Reference Adalimumab ABP501 (Amgen) US and EU Humira 40mg Randomised, single-blind, single-dose, three-arm, parallel-group study (1:1:1) Healthy volunteers (n=203) 90% CIs for the geometrical mean test-to-reference ratios for area under the serum concentration time curve (AUC) from time 0 extrapolated to infinity (AUCinf), AUC from time 0 to the last quantifiable concentration (AUClast) and maximum concentration (Cmax) were within the pre-specified equivalence criteria of 0.80 and 1.25. No subjects were positive for antibodies (ADA) at baseline. Over the course of the study 36 (54%), 38 (55%) and 45 (67%) participants in the ABP501, Humira (US) and Humira (EU) arms respectively developed binding ADAs. Neutralising ADAs were detected in 12 (18%), 15 (22%) and 14 (21%) subjects in the ABP501, Humira (US) and Humira (EU) arms respectively. [1] FKB327 (Fujifilm Kyowa Kirin Biologics) US and EU Humira 40mg Randomized, parallel-group study (1:1:1) Healthy volunteers (n=180) 90% CIs for the ratios of area under concentration–time curve up to last nonzero value (AUC0–t), area under concentration–time curve extrapolated to infinity and peak serum concentration (Cmax) geometric means were in the acceptance range for bioequivalence of 0.80–1.25 For the secondary PK parameter endpoints, was equivalent in all treatment comparisons; t½ 90%CI for the FKB327:US-Humira comparison extended below the pre-specified lower limit of 0.8 (0.78) whilst the two other comparisons were within the limit. Approximately 5% of subjects had detectable ADA at baseline. At last sampling, 69.5%, 73.3% and 70.0% of FKB327, Humira (EU) and Humira (US) participants respectively were positive for ADAs. [2] Drug
Table 1: THEME 3 (Outcomes) Summary of Investigator-Initiated Studies/Case Series for Epoetin Agent Reference Indication(s) Number of Patients Comments on Outcomes NHMRC Evidence Assessment 30 Level of Evidence NHMRC Evidence Assessment 30 Generalisability NHMRC Evidence Assessment 30 Applicability Epoetin zeta 33 Renal transplant recipients 10 switches 10 naïve Amongst switchers epoetin dose at 1 month was slightly higher than at baseline but not statistically significant (127± 99 vs. 117± 73 UI/kg per week) No drug-related adverse effects IV A A Epoetin alfa (Binocrit) 34 Elderly low-risk myelodysplastic syndrome patients 24 15 patients (62.5%) became transfusion independent and remained free from transfusion requirement for at least 3 months Conclusion: Binocrit is promising for the treatment of anaemia of MDS patients IV A A
Table 2: THEME 3 (Outcomes) Summary of Investigator-Initiated Studies/Case Series for Filgrastim Reference Indication(s) Number of Patients Comments on Outcomes NHMRC Evidence Assessment Level of Evidence NHMRC Evidence Assessment NHMRC Evidence Assessment 30 Applicability Filgrastim (Tevagrastim) 39 Allogeneic Hematopoietic Stem Cell Mobilisation and Transplantation in Patients with Acute Myelogenous Syndromes 48 total 24 Tevagrastim 24 Neupogen Similar yields of CD34+ stem cells were mobilised in the Tevagrastim (10.2x106 ,range: 2.52 to 35.4) group and the filgrastim (9.35x106, range: 3.7 to 30.6) historical control group Similar engraftment kinetics, hematopoietic reconstitution, and transplantation outcome were noted Donor side effects were mild, transient and not different groups III-3 (historic controls) B B Filgrastim (Zarzio) 40 Post Autologous Hematopoietic Stem Cell transplant to facilitate engraftment Mobilisation of Peripheral blood stem cell (PBSC) in patients undergoing autologous stem cell transplantation (AHSCT) 110 total 70 post AHSCT 40 PBSC mobilisation to AHSCT Biosimilar filgrastim following AHSCT is effective and generally well tolerated in the engraftment setting Kinetics of PBSC mobilisation and yield of CD34+ cells were comparable to the originator IV B B 3 trial
Filgrastim (Zarzio) 41 Peripheral blood stem cell (PBSC) mobilisation in healthy matched donors for allogeneic stem cell transplantation (allo-HSCT) 36 total 18 Zarzio 18 Neupogen No significant differences in the collection of the optimal cell dose 3/18 (16.6%) donors that received Zarzio failed to mobilise the optimal cell dose compared with 0% in the Neupogen group Platelet and neutrophil median time to engraftment was comparable between the two groups III-3 (retrospective) B B
SB5 (Samsung Bioepis Co Ltd) US and EU Humira 40mg Randomised, single-blind, single dose, three arm, parallel group study (1:1:1) Healthy volunteers (n=189) 90% CI for the ratio of treatment means for area under the concentration-time curve from time zero to the last quantifiable concentration (AUClast), from time zero extrapolated to infinite time (AUCinf) and maximal plasma concentration (Cmax) were within the pre-specified limits of 80-125% for the comparisons of SB5 with US Humira and SB5 with EU Humira, as well as for US and EU Humira. Twelve subjects were ADA positive at baseline (n=5 SB5; n=2 EU Humira; n=5 US Humira). ADA were detected in 185/189 subjects after treatment administration, with 68.3%, 73.0% and 65.1% of patients in the SB5, EU Humira and US Humira groups, respectively, exhibiting positive ADAs on Day 15 and 96.8%, 93.7% and 98.4% of patients in the SB5, EU Humira and US Humira groups, respectively, exhibiting positive ADAs on Day 71. The incidence of ADA development was not significantly different between the treatments. [1] Bevacizumab BI695502 (Boehringer Ingelheim) US and EU Avastin 1mg/kg Randomised, single-blind, single dose, three-arm, parallel group study (1:1:1) Healthy male volunteers (n=90) 90% CI for the ratio of treatment means for area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-tz), from time zero extrapolated to infinite time (AUC0-∞) and maximal plasma concentration (Cmax) were within the pre-specified limits of 80-125% for the comparisons of BI695502 with US Avastin and BI695502 with EU Avastin, as well as for US and EU Avastin. Not reported. [2]
Rituximab GP2013 (Sandoz) Rituxan (US) and MabThera (EU) 1000mg Randomised, double-blind, two dose, three-arm, parallel group study (1:1:2) Adult rheumatoid arthritis patients (n=312) 90% CI for the ratio of treatment means for from time zero extrapolated to infinite time (AUC0-∞) and maximal plasma concentration (Cmax) were within the pre-specified limits of 80-125% for the comparisons of GP2013 with Rituxan and GP2013 with MabThera, as well as for Rituxan vs MabThera. from time zero to the last quantifiable concentration was not assessed. 90% CI for the ratio of treatment means for peripheral CD19 positive B-cell count relative to baseline up to the second infusion on Day 15 were within the pre-specified limits of 80-125% for the comparisons of GP2013 with Rituxan and GP2013 with MabThera, as well as for Rituxan vs MabThera. The rate of binding ADAs was 16.5% in the GP2013 compared with 15.1% in originator rituximab treated patients. Five patients in the GP2013 arm and one patient in the originator rituximab arm exhibited neutralising ADAs. No differences in immunogenicity profiles between the treatments were noted. [3] trial
Figure 11 – Biosolids stabilisation grade in NSW and ACT Figure 12 – Biosolids stabilisation grade in QLD Figure 13 – Biosolids stabilisation grade in South Australia Figure 14 – Biosolids stabilisation grade in Tasmania Figure 15 – Biosolids stabilisation in Victoria Figure 16 – Biosolids stabilisation grade in WA and NT Biosolids management can be separated into two main categories, treatment and beneficial use. These categories can be further broken down into the following main steps: Treatment dewatering stabilisation storage (at treatment plant) The two main in treating biosolids are stabilisation and dewatering. Stabilisation reduces the levels of pathogens and odour potential of biosolids. Dewatering removes water and hence reduces the volume of biosolids for subsequent use. Dewatering is an important step in improving the handling characteristics of biosolids and reducing the cost of subsequent management. The most common biosolids treatment processes are shown in the figures below. No data is currently available on biosolids storage.
STAT 405 – Biostatistics ~ Assignment #9 (102 points) 1. Mayo Clinic Lung Cancer Data Description: Survival in patients with lung cancer at Mayo Clinic. Karnofsky performance scores rate how well the patient can perform usual daily activities Variable Names: inst: Institution code (DO NOT USE IN YOUR ANALYSIS) time: Survival time in days status: censoring status 0=censored, 1=dead age: Age in years sex: Male=1 Female=2 ph.ecog: ECOG performance (0=good 5=dead) ph.karno: Karnofsky performance score (bad=0-good=100) rated by physician pat.karno: Karnofsky performance score rated by patient meal.cal: Calories consumed at wt.loss: Weight loss in last six months Download Lung.txt from the course website and then source it into R. Then do the following to make sex a factor variable and fix the censoring variable so censor = 0 and dead = 1. > source(file.choose()) locate the Lung.txt file in your directory. > Lung$sex = as.factor(Lung$sex) > Lung$status = Lung$status – 1 a) Perform a test so see if the survival experience differs across gender. Obtain and plot the Kaplan-Meier estimates for both genders. Discuss. (4 pts.) b) Fit a using age, sex, ph.ecog, ph.karno, pat.karno, meal.cal, and wt.loss. Briefly summarize the model (don’t compute HR’s), which variables appear to be significant? (4 pts.) c) Test proportional hazards assumptions for the significant covariates (p < .10). Which variables appear to have a violation of proportional hazards assumption? Include plots from the cox.zph function in support of the p-values from the PH test. (4 pts.) trial
Location German Biogas Association (Fachverband Biogas) Invalidenstr. 91 10115 Berlin, Germany Friday, 17-06-2016 – Inter-Association workshop Time Topic Moderator / Presenter 09:00 - 09:30 Arrival and coffee 09:30 – 09:40 Welcome & Introduction to Workshop Frank Hofmann (GBA) and Stefano Proietti (ISINNOVA) 09:40 – 09:50 The present status and future prospects of the biogas/biomethane industry in Europe Jan Stambasky (EBA) 09:50 – 10:00 Biomethane roadmap for Germany Frank Hofmann (GBA) 10:00 – 10:10 Biomethane roadmap for Austria Franz Kirchmeyr (AKB) 10:10 – 10:20 Biomethane roadmap for France Marie Verney (ATEE) 10:20 – 10:30 Biomethane roadmap for Hungary Kornel L. Kovacs (HBA) 10:30 – 10:40 Biomethane roadmap for Italy Lorenzo Maggioni (CIB) 10:40 – 10:50 Biomethane roadmap for the United Kingdom David Collins (REA) 10:50 – 11:00 Coffee Break 11:00 – 11:40 Sustainable biomethane production - Relevant Sustainability and Management practices in different countries Kristin Sternberg (FNR) 11:40 – 12:20 Carbon footprinting within the context of the BIOSURF project Stefan Majer (DBFZ) 12:20 – 13:00 Concept for biomethane cross-border trade administration Biomethane mass balancing case before the European Court of Justice Attila Kovacs (EBA), Max Peiffer (Energy Lawyer) 13:00 – 13:10 Conclusions 13:10 – 14:30 Buffet Lunch 14:30 End of the event
Proposed medicines list Mydriatics: atropine sulphate 0.5% atropine sulphate 1% cyclopentolate hydrochloride 0.5% cyclopentolate hydrochloride1% tropicamide 0.5% tropicamide 1% Anaesthetics: lidocaine hydrochloride 4% and fluorescein sodium 0.25% oxybuprocaine hydrochloride 0.4% proxymetacaine hydrochloride 0.5% tetracaine hydrochloride 0.5% tetracaine hydrochloride 1% Stains and dyes: fluorescein sodium 1% fluorescein sodium 2% Antibacterials chloramphenicol 0.5% and 1% PLUS: non-prescription eye drops for supply in the course of professional practice including phenylephrine hydrochloride 2.5% and ocular lubricants
14 25, 27 Bioinformatics NCBI website 15 May 2, 4 Next-Generation Sequencing May 11th Final Exam 7:15 am – 9:15 pm Lecture and lab weeks 13-15; specific topics from throughout the semester as designated by the instructor ***** You are expected to arrive prepared for laboratory work designated by the instructor during the previous Absolute preparation includes: Lab notebook Necessary protocols or SOPS printed out and pages inserted into notebook Black permanent pen Lab coat Safety goggles or glasses Calculator Tentative laboratory schedule Week Date Activity Reading 1 Jan. 24, 26 Laboratory introduction; lab safety; micropipette use ppt; lab math review; keeping a lab notebook ppt; begin micropipette use; Micropipette validation exercise HO - SOP hand washing and gloving; micropipette validation SOP; pH meter use SOP; SOP for 1M pH 8; HO – media prep SOP; pouring plates SOP; SOP for Prep of 10x TBE 2 31, Feb.2 Begin solution preparation; use of pH meter: calibration exercise and prep of 1 M Tris-HCl, pH HO – transformation of E. coli SOP; spreading plates SOP; picking single
BIOTECHNOLOGY RESEARCH LABORATORY S.No Name of Equipment Make Application 1 High Performance Liquid Chromatography SHIMADZU & LC2010CHT Quantitative and qualitative analysis of liquid samples 2 Biodiesel Rancimat METROHM & 893PROFESSIONAL BR Determination of the oxidative stability of biodiesel 3 Rotary Vacuum Evaporator EQUITRON & ROUND BATH RUTEUA Purification of sample after solvent extraction 4 Accelerated Solvent Extractor THERMO SCIENTIFIC & DIONEX ASE 150 Rapid extraction of desired product by use of organic solvent. 5 Laminar Airflow Chamber GENUINE Microbial transfer under sterilized condition 6 Autoclavable Fermentor BIOSPIN – OSA &BIO-AGE EQUIPMENT SERVICE Culturing and harvesting of microbes using fermentation
7 Large Volume Centrifuge SCIENCE WORLD(SIGMA) Separation of substances on relative density in liquid suspension 8 Thermomixer EFFENDORF& Vortexing samples under controlled temperature 9 Ultra Sonicator CHEM LABS BANGALORE Dispersion of liquid ultrasonic wave bath. 10 Incubator Shaker THERMO SCIENTIFIC &SHKE6000-8CE Maintenance of suspended condition for microbial growth 11 Fully Automatic Autoclave EQUITRON Sterilization of microbial medium 12 Moisture Analyser WENSAR & WENSER HMB100 Determine the amount of moisture content present in any or semi solid sample 13 Tissue Tearor UNIDRIVE X 1000 & CAT Disruption of microbial cell wall 14 Cold Storage Chamber F-MAXX & SZ-7524-P It is maintained 50c, so as to pressure any kind of samples from biological degradation or microbial activity
d. Identification of Issues/concerns with supporting statements, diagrams, charts, etc.. e. Your position on the case with supporting statements, diagrams, charts, etc… f. Closing Evaluation Your presentation will be evaluated as a group based on the following rubric… Objective Beginning 1 Developing 2 Accomplished 3 Exemplary 4 Score Identification of DNA technology present in case Some connection made between the case and a DNA technology. Missing a clear description of the technique Connection made between case and DNA technology. Some of description demonstrates understanding of technique Technology technique correctly identified with a general description of the technique. May use charts/diagrams. Technology technique correctly identified. Description is clear and appropriately detailed. Use of charts/diagrams.
Topic covered: Transgenic Animals – Mice, Cow Week:5 Unit:2 Assignment:searching ppt on pig Topic covered:. Transgenic Animals –, Pig, Sheep, Goat, Bird, Insect Week:6 Unit:2 Assignment: make a comparative on these diseases Topic covered: . Animal diseases need help of Biotechnology – Foot-and- mouth disease, Trypanosomiasis, Theileriosis. Week:7 Unit:2 Assignment: draw a comparative Topic covered: . Animal diseases need help of Biotechnology Trypanosomiasis, Theileriosis. Week:8 Unit:3 Assignment:make a chart on method of animal clones Topic covered: Animal propagation – Artificial insemination, Animal Clones. Week:9 Unit:3 Assignment: searching this technique Topic covered:Animal Biology – Embryo transfer techniques. Week:10 Unit:3 Assignment: study the ppt Topic covered:Introduction to Stem Cell Technology and its applications. Week:11 Unit:4 Assignment: presentation on gene therapy
Week:-7 unit(2) Topic:- ) schelminthes: General features, Outline of classification, Pathogenic roundworms and their vectors in relation to man: Parasite adaptation Assignment:-patogenic roundworm Week:-8 unit(3) Topic:- Annelida:-General features, Outline of classification, Coelom: Metameric segmentation, Assignment:- to study the slide of annelida Week:-9 Unit(3) Topic:- Earthworm vermicomposting Assignment: search on internet about vermicompost Week:-10 (unit 3) Topic:-Arthropoda: General Features, Outline of Classification; Larval forms of crustacean, Respiration in Arthropoda; Metam orphosis in insects; Social insects; Insect vectors of diseases; Assignment:-study the slide of arthropoda Week:-11 (unit 3) Topic:- Metamorphosis in insects; Social insects; Insect vectors of diseases; Assignment:-vector disease Week:-12 (unit 4) Topic:- )Mollusca : general features, Outline of classification, Shell Diversity; Torsion in gastropoda, Life history of Pila. Assignment:-life history of pila
Dr. Christopher Reid is currently Technical Lead Engineer and Principal Investigator at Boeing. Dr. Reid utilizes systems interaction, systems safety, and ergonomics approaches to develop and integrate processes, tools, and technologies that make the aerospace manufacturing and service environments more conducive for mechanics to work in across the different business units. He is a graduate of the University of Central Florida in Orlando, earning degrees in Electrical Engineering Technology and Industrial Engineering. Dr. Reid has worked at Boeing’s Frederickson and Everett WA locations supporting 787, 747, and 767 programs. More recently, Dr. Reid was the BR&T Human Factors & Ergonomics Team and Lab Lead in Charleston, SC. Dr. Reid has also worked for Lockheed Martin on astronaut spacesuit assessment and design as a Human Factors & Ergonomics Discipline Lead at NASA Johnson Space Center (Houston, TX). He was a Human Factors Engineer for the US Army Natick Soldier Research, Development & Engineering Center working on personal protective equipment such as body armor for the US Warfighter (Natick, MA). In his free time, Dr. Reid spends time with his family, plays video games, and is an avid soccer player.
* B I O - D A T A * 1. NAME : Dr. Muley Dipak Vishwanathrao 2. BIRTH DATE : 20/12/1957 3. DESIGNATION : Professor 4. ADDRESS : Department of Zoology : Shivaji University, Kolhapur-416004 : 0231- 2609248 (O) 91 + 09421918134 (M) E-mail : 5. ORGANISATION : Shivaji University, Kolhapur. 6. EDUCATIONAL QUALIFICATIONS : Degree Class Institution/ University Year of Passing B. Sc. IInd Nagpur University, Nagpur 1978 M. Sc. Ist Marathwada University, Aurangabad 1981 Ph. D. By Thesis Marathwada University, Aurangabad 1985 7. EXPERIENCE : Teaching Experience: 21 years (Dec.1987–Mar. 2008) Deptt. of Zoology, Shivaji University, Kolhapur. Administrative Experience: 5½ years Registrar- 2 years (25th March 2008 to 24th March 2010) Dr. BAM University, Aurangabad. Registrar- 3½ years (15th June 2010 to till date) Shivaji University, Kolhapur. I/c Head, Deptt. of Zoology, S. U. K. 2nd July 2011 to 31st Dec. 2011. 4th Nov. 2013 to till date. 8. AREA OF SPECIALISATION: Subject : Fisheries Science Research : Aquatic Toxicology and Environmental Biology Title of Ph.D. thesis : ‘Effect of Pollutants on Freshwater Molluscs from Godavari River at Paithan’. 9. RESEARCH PUBLICATIONS : See Appendix I 10. CONFERENCE PARTICIPATION : See Appendix II
11. RESEARCH GUIDANCE : See Appendix III 12. OTHER ASSIGNMENTS : See Appendix IV 13. VISITS ABROAD Nagoya Agriculture University, Nagoya, JAPAN. University of Hoenheim, Stuttgart, F.R.G. Institute of Tropical Medicine, Tubingen, F.R.G. Zoologisches Institute, University of Heidlberg, F.R.G. APPENDIX -I Paper Published in Journals 76 Published in Proceedings 14 Total Publications 90 H-index 5 I10 index 3 Research gate score 5.73 LIST OF PUBLICATIONS (In Journals) Mane, U.H., Muley, D.V. and S.R. Akarte (1983): Toxicity of Endosulfan 35 EC to freshwater and estuarine bivalves- Acute toxicity and oxygen consumption. Indian J. Comp. Anim. Physiol. 2: 1-9. Mane, U.H., Akarte, S.R. and D.V. Muley (1984): Effect of cyathion-malathion on respiration in three freshwater bivalve molluscs from Godavari river near Paithan. J. Environ. Biol. 5(2): 77 - 80. Mane, U.H. and D.V. Muley (1984): Acute toxicity of Endosulfan 35 EC to two freshwater bivalve molluscs from Godavari River at Paithan, Maharashtra State. Toxicology Letters. 23: 147-155. Kulkarni, D.A., Rao, K.R. D.V. Muley and U.H. Mane (1986): Biochemical reserves of mantle and adductor muscles of three freshwater lamellibranch molluscs. Uttar Pradesh Journal of Zoology 6(1): 134-141. Muley, D.V. and U.H. Mane (1986): Endosulfan toxicosis to the hepatopancreas of lamellibranch moluscs. Utter Pradesh Journal of Zoology 6(2): 194-200.
Organisation: INFORSE-Europe and ECOS Name: Gunnar Boye Olesen and Stamatis Sivitos Date: May 4, 2012 ENER Lot 20: Local room heating products Document comment relates to Section in document Page number Topic Comment Proposed change All n.a. n.a. General Room heaters are converting a large share of Europe's energy supply into space heating. They consume as much as 1/3 of the consumption of boilers, the energy using product with the largest use in Europe. Combining this with the large improvement options for many of the room heaters, there are significant opportunities to save energy with Ecodesign and labelling regulations for these products. The Ecodesign product regulation must complement building regulations, which in some countries it gives clear guidance on where to use and where not to use certain room heating products, such as electric heaters. See following proposals Task 5 report and following 5.1.4 14ff Energy Consumption calculation The choice of methodologies to evaluate the efficiency of room heaters in the preparatory studies are not based on a seasonal efficiency and are not harmonised among the base cases with a similar function (such as residential space heating ). The lack of a coherent and adequate methodology weakens the identification of improvement options and comparison of the different room heating technologies. We therefore propose to use seasonal efficiency for the Efficiency calculations for room heaters are changed to seasonal efficiencies for all products covered (all base cases). The method must include the effects of controls including different thermostats. Where test and calculation standards are not in place for seasonal efficiency (including testing), the preparatory study shall highlight the missing standards and propose transitional measures until standards can be in load
01_Stelarc.jpg Source file: [Biotopia-7745.jpg] & [Ear On Arm.jpg] Uploaded: 01.02.2012 Stelarc, ‘Internet Ear’, 2010. With Internet Ear the Australian artist Stelarc ventures into a controversial area: the fusion of the human body with technology. By means of a lengthy surgical process the artist had an artificial human ear implanted in his forearm. A subsequent operation then installed microscopic electronic equipment in this third ear, with a view to both transmitting and receiving sound. Because of the danger of possible infection it was impossible to give the ear a technological “sense of hearing” and the equipment was removed. But the ear is still attached to Stelarc’s arm. Ear on arm. Internet Ear, which was commissioned by PORT 2010 for the Biotopia exhibition, launches the Ear on Arm project onto the Internet. With this project Stelarc aims at the limitation of infection with almost poetic, or rather epic, implications. A series of his arm with ear have been cast in polyurethane. They do not see, but “ear” the world around them. The other factor at work in Ear on Arm, the exploration of technological sensuality, now becomes a sensuality that is distributed and expanded; a sensual technology disconnected from its original “host” and, in principal, beyond its control. We hear with Stelarc’s ear! The phrase “Lend me your ear”, in the words of the Beatles (and before them, Shakespeare (Julius Ceasar), becomes real. Stelarc actually does lend us his ear. But what will you say?
Antiseptic Comparison Lab – Flow Chart Antiseptic Comparison Lab – Data Quadrant Antiseptic applied Size of Halo (in mm) A Sterile distilled water B Garlic C D Halo Size A B C D Station 1 Station 2 Station 3 Station 4 Station 5 Station 6 Station 7 Station 8 Average
A 90 – 100% B 80 – 89% C 70 – 79% D* 60 – 69% F 50 – 59% COURSE EXPECTATIONS and GUIDELINES WEIGHTING OF TASKS and Q-SHELL ASSIGNMENT CATEGORIES: Tests and Quizzes 40% Engineering Practices, Labs and Projects 15% Daily Homework, Notes, and Classwork 25% Semester Final 20% HOMEWORK: Homework will be related to the curriculum and will be assigned to strengthen skills, reinforce concepts, and/or prepare for a lesson, unit, or activity. Students should expect some homework on a daily basis. are two general categories of homework: Peer evaluated: In cooperative groups, students will evaluate work in interactive notebooks as either following or not following the guidelines. Instructor evaluated: This includes online assessments, projects, concept-mastery worksheets, and lab conclusions. LATE WORK AND/OR MISSING WORK: Each assignment will have a due date. This is the date by which you are expected to submit the assignment. Missing work will be recorded in the grade book as a zero. If a student is absent from that student is responsible for making up missed work. EXTRA CREDIT: Individual Extra Credit: There are select opportunities for a small amount of individual extra credit to be earned. These will be discussed in class. Group Extra Credit: Large assignments for extra credit will be considered on a class-level basis, not an individual basis, and will only be offered to students who have all assignments completed.
Full Name: Jordan Green Designation/Rank: Navy Diver Petty Officer Second Class Status: Navy, Active Duty Hometown: Current Command: Seal Delivery Vehicle Team One, Previous commands: USS Rushmore (LSD-47) Injury type: Lower Body Impairment Date of injury: March 20, 2009 Rejoin a SEAL platoon Earn a Bachelor’s degree Travel Warrior Games events: Swimming: 100M Free Swimming: 50M Breaststroke Navy Diver Second Class Jordan Green “It’s not the circumstances that determine who you’re going to be but how you deal with these problems and pains that come your way” - Mat , “Girl ” Navy Diver Petty Officer Second Class (ND2) Jordan Green joined the Navy in February 2006. His first duty station was aboard the USS Rushmore (LSD-47), After completing one Rim of the Pacific (RIMPAC) deployment he was hand selected to attend Navy Search and , He not only completed the school number one in his class but was awarded Honor Man of his class. In 2008, during normal operations off the coast of a civilian was spotted drifting on a boogie board and near death. The man overboard call was given and ND2 Green was able to battle rough seas to save the man’s life. Later that same year Green was selected for the U.S. Navy Dive Program out of a competitive field of applicants. He attended the Naval Diving and , City, Upon graduating second overall in his class he received orders to Seal Delivery Vehicle Team One (SDVT1), . While on a training operation in 2009 ND2 Green was injured after he provided aid to a downed Navy SEAL following a parachuting exercise. As he was boarding the rescue boat it became caught in the surf zone. A large wave broke over the bow, ripping him from the side of the boat and his right leg collided with the propeller. After 13 surgeries and a year of physical therapy, on Feb. 5, 2010, Green passed a physical screening test to return to Full Diving Duty. He is currently still at SDVT-1 and plans on joining a SEAL platoon in the near future. He is also pursuing a bachelor’s degree and a civilian dive certification to become a scuba instructor.
33 16099002 Ms. Shivani Kapoor Studies on development of electrochemical sensor based on nanomaterial modified electrodes for detection of chemical explosives Dr. Neeraj Dilbaghi Dr. Sandeep Kumar 07.05.2016 34 16099003 Ms. Meenakshi Pahwa Development of Bacillus species as Plant Growth Promoting Rhizobacteria for Dry Land Farming Dr. Namita Singh Dr. K.K. Kapoor 28.06.2016 35 16099004 Ms. Minakshi Lalit Development of molecularly imprinted polymer sensor for selected Cyanotoxin Dr. Namita Singh …….. 28.06.2016 36 16099005 Ms. Shruti Dudeja Studies on antimicrobial activity of bioactive compound(s) from fungi isolated from different sources Dr. Anil Kumar …….. 28.06.2016 37 16099006 Ms. Jyoti Sheorain Synthesis, Characterization and Biological Evaluation of Thymol nanoformulations Dr. Santosh Kumari …….. 28.06.2016 38 16099007 Ms. Chanchal Identification and characterization of genes with respect to secondary metabolism in Asparagus racemosus Dr. Vinod Chhokar …….. 28.06.2016
Consist of long chains of monosaccharides Usually polymers of glucose monomers Joined by glycosidic linkages (yields May be simple linear molecules But some are branched (more complex) &/or have cross-links between chains Different structures & functions depend on how the monomers are linked together Starch: Plants Branched & unbranched forms See as large granules within chloroplasts Glycogen: Animals Highly branched See as granules (smaller than starch) in cytosol Lots in liver & muscle cells Starch and glycogen are both alpha-glucose polysaccharides Cellulose: Beta-glucose polysaccharide O-H orientation makes it hard to digest Plant cell walls Hydrogen-bonding between chains strong microfibrils Most abundant organic compound on earth Animals can only digest cellulose if they have symbiotic bacteria in their guts Cows Termites Chitin: Fungal cell walls and insect exoskeletons Monomers have an extra nitrogen-containing side-chain added to glucose Poorly soluble in water however soluble in non-polar solvents. Grouped dependent on solubility. The different groups are: Fats & oils – for energy storage, insulation and cushioning Phospholipids – animal cell membrane structure
Biology Week #10 Week of: October 20th-24th Day Root Words In-Class Homework 10/20: Monday Word: Definition: As in: - Picture: -Second Quarter Sheet and Review Goals -Organize Binder -Review Midterm -Pretest on Homeostasis - Grade Graph 10/21: Tuesday Word: Definition: As in: - Picture: -Bill Nye Clip -Periodic Table Activity 10/22: Wednesday Word: Definition: As in: - Picture: -LATE ARRIVAL!! -Notes -Compounds vs. Mixtures 10/23: Thursday Word: Definition: As in: - Picture: -Notes on water -Willy the Water Strider Lab 10/24: Friday Word: Definition: As in: - Picture: -Quiz over basic Chemistry! -Turn in week 10 packet or mrlscience.weebly.com Bill Nye the Science Guy Video – Atoms
Biology Week #13 Week of: November 10th – 14th Day Root Words In-Class Homework 11/10: Monday Word: Definition: As in: - Picture: -Organize Binder/Goals -Notes on Homeostasis -Grade Graph -Begin movie “Contagion” 11/11: Tuesday Word: Definition: As in: - Picture: -NO SCHOOL! VETERANS DAY! 11/12: Wednesday Word: Definition: As in: - Picture: - Movie “Contagion” 11/13: Thursday Word: Definition: As in: - Picture: -Finish “Contagion” -Review how diseases and viruses spread 11/14: Friday Word: Definition: As in: - Picture: -Quiz over Diseases! -Turn in week 13 packet Need Help? Talk to me in I’m available during periods 4, 5 and 8. You can call me at or email Also, Mr. Hill is in the Tutoring Center before school on Tuesdays and Thursdays. Be sure to use the website mrlscience.weebly.com Why Should I Care About Germs?
Biology Week #21 Week of: January 19th – 23rd Day Root Words In-Class Homework 1/19: Monday Word: Definition: As in: - Picture: -No School 1/20: Tuesday Word: Definition: As in: - Picture: -Goals -Reflection/Pink Notes on Photosynthesis -Grade Graph/Quiz Review 1/21: Wednesday Word: Definition: As in: - Picture: -Notes on Calories and Cellular Respiration 1/22: Thursday Word: Definition: As in: - Picture: -Go Over Homework -Finish Cellular Respiration Notes 1/23: Friday Word: Definition: As in: - Picture: -Week #21 Quiz -Finish Packet Need Help? Talk to me in class. I’m available during periods 4, 5 and 8. You can call me at or email Also, Mr. Hill is in the Tutoring Center before school on Tuesdays and Thursdays. Be sure to use the website mrlscience.weebly.com What are Calories?
Bio Science Week #28 Week of: March 9 - 13 Day Root In-Class Homework 3/9: Monday Word: Definition: As in: - Picture: -Grade Graph -Finish Pink -Planarian Lab 3/10: Tuesday Word: Definition: As in: - Picture: - Planarian Conclusion 3/11: Wednesday Word: Definition: As in: - Picture: -Late Arrival - Sex Pre-Test - on Mitosis vs. Meiosis 3/12: Thursday Word: Definition: As in: - Picture: -Finish Notes -Meiosis Flipbook 3/13: Friday Word: Definition: As in: - Picture: -Week #28 Quiz -Google Classroom Need Help? Talk to me in class. I’m available during periods 4, 5 and 8. You can call me at or email Also, Mr. Hill is in the Tutoring Center before school on Tuesdays and Thursdays. Be sure to use the website mrlscience.weebly.com Mitosis Vs. Meiosis Problem: How do we make babies with the correct number of chromosomes?
(BB, Bb) (bb) Dimple (DD, Dd) Green No Dimple (dd) Lime Freckle (FF, Ff) Copper No Freckle (ff) Red Free Ear Lobes (GG, Gg) Gold Attached Ear Lobes (gg) Caramel Middle digit hair (HH, Hh) Yellow Hairless Middle Digit (hh) Orange PTC taster (JJ, Jj) Jade (jj) Dark Pink Dark Hair (MM, Mm) Black Light hair (mm) White Widow’s Peak (PP, Pp) Trans. Pink No Peak (pp) Trans. Blue Tongue Roller (SS, Ss) Mulberry Cannot roll tongue (ss) Brown Conclusion: Are all dominant traits more common? USE AT LEAST THREE DIRECT EXAMPLES FROM THIS LAB TO ANSWER THE QUESTION.
BiologyE Week #35 Week of: May 4th – 8th Day Root Words In-Class Homework 5/4: Monday Word: Definition: As in: - Picture: to Antibiotic Resistance Lab 5/5: Tuesday Word: Definition: As in: - Picture: -Set up Antibiotic Resistance Lab 5/6: Wednesday Word: Definition: As in: - Picture: -Late Arrival! -Candy Corn Evolution Lab 5/7: Thursday Word: Definition: As in: - Picture: -Finish Antibiotic Resistance Lab 5/8: Friday Word: Definition: As in: - Picture: -Evolution Post Test -Finish Antibiotic Resistance Lab Need Help? Talk to me in class. I’m available during periods 4, 5 and 8. You can call me at or email Also, Mr. Hill is in the Tutoring Center before school on Tuesdays and Thursdays. Be sure to use the website mrlscience.weebly.com Evolution Reading Darwin’s Epic Journey
Biology Weeks #7-8 Week of: September 29 – October 8 Day Root In-Class Homework 9/29: Monday Word: Definition: As in: - Picture: -Grade Graph -Goal Setting -Research Experiment 9/30: Tuesday Word: Definition: As in: - Picture: -Write out Plant Experiment 10/1: Wednesday Word: Definition: As in: - Picture: -Set-up Plant Experiment 10/2: Thursday Word: Definition: As in: - Picture: -Plant Experiment 10/3: Friday Word: Definition: As in: - Picture: -Quiz on Scientific Method -Plant Experiment 10/6: Monday Word: Definition: As in: - Picture: -Get Results and Finish Experiment 10/7: Tuesday -FIELD TRIP TO OAK PARK CONSERVATORY! 10/8: Wednesday Word: Definition: As in: - Picture: -Late Arrival -Present Plant Experiments to Class Need Help? Need Help? I prefer if you make an appointment. You can call me (708) or email clundgren@oprfhs.org or mrlscience.weebly.com
34. A Tt is crossed with a Tt plant. A) Complete a Punnett Square: B) What percentage of the offspring will be short? ______ 35. A heterozygous round seeded plant (Rr) is crossed with ahomozygous round seeded plant (RR). A) Complete a Punnett Square: B) What percentage of the offspring will be homozygous (RR)? ____________ 36. A homozygous round seeded plant is crossed with a homozygous wrinkled seeded plant. A) What are the genotypes of the parents? __________ x __________ B) Complete a Punnett Square: C) What percentage of the offspring will also be homozygous? ______________ 37. In pea plants purple flowers are dominant to white flowers. A) If two white flowered plants are cross, what percentage of their offspring will be white flowered? ______________ B) Complete a Punnett Square:
Biology Quarter 3: Weeks 24-25 February 22 - March 5, 2010 DATE IN CLASS HOMEWORK Monday-Tuesday (1,5; 95 min.) 2/22-23 Lab: DNA Compaction Introduce Protein Synthesis *How are DNA molecules packed into short chromosomes? 1. Biology 12.3 Interactive DUE: 2/24-25 2. Journal Entry #3 DUE 3/4-5 Wednesday-Thursday (1; 80 min. 5; 95 min.) 2/24-25 Protein Synthesis *What is the difference between DNA and RNA? 1. Biology 12.4 Interactive Notes DUE: F 2/26-3/1 2. Journal Entry #3 DUE 3/4-5 Friday-Monday (1,5; 95 min.) 2/26-3/1 Protein Synthesis Mutations, Gene Regulation *What role do mutations play in the evolution of humans? 1. Biology 13.1-2 Interactive Notes DUE: T-W 3/2-3 2. Journal Entry #3 DUE 3/4-5 3. Check for Understanding DUE 3/2-3 Tuesday-Wednesday (1; 95 min. 5; 80 min.) 3/2-3 BioTechnology: Forensic DNA Fingerprinting *How do investigators prepare for a crime scene? 1. Biology 13.4 & 14.3 Interactive Notes DUE: Th-F 3/4-5 2. Prelab 3. Journal Entry #3 DUE 3/4-5 Thursday-Friday (1,5; 80 min.) 3/4-5 BioTechnology: Forensic DNA Fingerprinting *How are DNA fingerprints analyzed? *How do restriction enzymes produce a DNa fingerprint? 1. Biology 15.1-2 Interactive DUE: M-T 3/8-9 Molecular Genetics Protein Synthesis RNA structure and types of RNA Transcription Translation regulation Historical Genetic Engineering
Date Biology Tues 9/3 HALF DAY PBIS What is Biology Ice breakers Getting to know you assignment Wed 9/4 PBIS Go over syllabus and classroom expectations Thur 9/5 PBIS Lab safety contract read through Skills Review Packet Fri 9/6 PBIS Study skills What does it mean to be alive “Glue Monster Activity”
Scatter Plot Behavior Monitoring Student: School/District: Observer/Recorder: Start Date: End Date: Activity Time Day1 Day2 Day 3 Day 4 Day 5 Day6 Day 7 Day 8 Day 9 Day10 per time period By Code Total Coding The chart is divided into 15 or 30 minute intervals. Displaying expected behavior = Displaying targeted behavior =
Antecedent (prior to behavior) Alone with peers beginning an activity ending an activity participating in group asked to do something told not to do something transitioning recess being ignored lunch given a warning working on academics: ________________ Other ________________ Behavior refusal verbal outburst verbal threats crying destroying property physical aggression ________________ out of seat running away other _________________ Consequences verbal redirection nonverbal cue/signal loss of privilege behavior is ignored change assignment remove from area time out sent from room: ________________ detention suspended physical management other ________________ Duration (how long did it last) < 1 minute 1-5 minutes 5-10 minutes 10-30 minutes ½ hour – 1 hour 1-2 hours 2-3 hours 3 + hours Intensity 1 LOW 2 3 4 5 HIGH ABC Chart
Executive Dean: Higher Education Criteria Essential / Desirable Method of Assessment Qualification PhD or Professional Doctorate in a relevant academic area. E Application Form and Certificates PGCE or other equivalent teaching Qualification. E Application Form and Certificates Knowledge and Experience Proven record of management of a large and diverse team. E Application Form/Assessment Centre Successful and recent experience in all aspects of quality processes including assurance and enhancement. A full and through understanding of the QAA code and its practical implementation is crucial. E Application Form/Assessment Centre Experience of strategic planning to deliver sustainable organisational improvement. E Application Form/Assessment Centre Significant recent management and leadership experience across the full breadth of the Qualifications Framework. E Application Form Demonstrable experience of effective resource delivery. D Application Form/Assessment Centre Experience of effective staff development and appraisal. D Application Form A demonstrable record of publications and / or evidence of esteem in a professional context. E Application Form Have significant experience of strategic leadership and demonstrate a successful track record of collaborative working internally and externally. E Application Form / Assessment Centre Skills and Abilities Demonstration of curriculum development linked to employer needs and student employability. E Assessment Centre Excellent interpersonal, leadership and high level communication skills, including the ability to support, motivate and inspire teams and individuals. E Application Form/Assessment Centre Evidence of successful leadership of a dynamic academic and business support staff to deliver high quality education and training. E Assessment Centre Proven ability to new ideas and initiatives that enhance the curriculum offer and overall student experience. E Assessment Centre
Have you ever lived in a home that did not allow pets? Yes No How would you describe your home environment? Moderate Easy-going Are you able to provide a home for this pet’s entire life (Please consider finances and medical needs)? Yes No Maybe Do you foresee any major changes in the next 15 years? Mark X to what applies or Marriage Children Health issues College circle what applies. Graduation Moving Pets Other: Circle or X any reason that you wish to adopt this pet. Family Pet Child’s Pet Pet Gift Companion Service animal Breeding Showing Companion for Pet Circle or X any reason/ circumstance that you would justify to give up a pet? Moving New Baby Divorce Marriage Molting Loss of interest Time Consumption Person Allergies/Medical Problems Animal Medical Problems Animal training Problems Size/Activity of animal Escaping enclosure/ cage Not getting along with current pets Behavioral Problems Other: How do you plan on handling exercise, enrichment and excrements? How many hours will your pet spend home alone per day on average? Few (Less than 5) Average (6-9 hours) Many (10-14) Other: will your pet stay when on a typical day? (check all that apply) In an enclosure in Loose in house outside In enclosure outside Both indoor and outdoor access In one room of house In garage In barn Please detail the arrangements you have made for this pet to live in your home. Where will your pet stay when home alone? (check all that apply) In an enclosure in house in house Loose outside In enclosure outside Both indoor and outdoor access In one room of house In garage In barn Are you willing to adopt a pet with medical issues or special needs? Yes No Maybe, it depends
Has any pet died on your property in the last 12 months a contagious disease such as parvo, distemper, rabies or parasitic infections? Yes No Unknown Have you ever euthanized an animal? Yes No What do you consider legitimate circumstances to euthanize an animal? Have you ever surrendered an animal to a pound or shelter? Yes No Have you ever given an animal away? Yes No Do you agree not to surrender the animal you adopt from AAAS to anyone other than AAAS? Yes No It Depends Have you ever adopted from AAAS? Yes No How did you hear about AAAS? Please List your Previous Pet that you no longer have (most recently) Pet Name Type (i.e. dog, cat) Breed Age Gender Spayed or neutered? Up to date Medically i.e. Shots Preventions Living Environment (indoor/ outdoor) Reason you no longer have? Please List your Current Pets Pet Name Type (i.e. dog, cat) Breed Age Gender Spayed or neutered? Up to date Medically (i.e. Shots Preventions) Living Environment (indoor/ outdoor) Any Health conditions?